{"disease":{"id":"marginal-zone-lymphomas","name":"marginal zone lymphomas"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT02362035","title":"ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":161,"lead_sponsor_name":"Acerta Pharma BV","has_results":true},{"nct_id":"NCT01474681","title":"Safety and Tolerability of HSC835 in Patients With Hematological Malignancies","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":27,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true}],"total":2},"guidelines":[],"source":"Drug Landscape verified database"}